President Donald Trump’s physician, Dr. Sean P. Barbabella, announced that after conducting a battery of tests, he found that ...

Cambridge: Moderna, Inc. has announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.

Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...

The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from ...

(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

Moderna, Inc. remains under pressure in 2025, despite recent next-gen COVID vaccine approval & cancer vaccine trial. Learn ...

The U.S. government has awarded Kernal Bio and three other sub-awardees up to $48 million to help advance the biotech’s in vivo mRNA-encoded CAR T-cell program. In an interesting—if not somewhat ...

Since 1965, messenger RNA (mRNA) vaccines have been studied for cancer treatment, but it was the technological advances in vaccines during the COVID pandemic that helped accelerate research. Currently ...

EDITOR’S NOTE: The views expressed in this commentary are solely those of the writer. CNN is showcasing the work of The Conversation, a collaboration between journalists and academics to provide news ...

Deborah Fuller receives funding from the National Institutes of Health. She is co-founder and a scientific advisor for two biotech companies developing nucleic acid vaccine technologies that are not ...